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Background: A previous meta-analysis found that high dose zinc acetate lozenges reduced the duration of common
colds by 42%, whereas low zinc doses had no effect. Lozenges are dissolved in the pharyngeal region, thus there might
be some difference in the effect of zinc lozenges on the duration of respiratory symptoms in the pharyngeal region
compared with the nasal region. The objective of this study was to determine whether zinc acetate lozenges have
different effects on the duration of common cold symptoms originating from different anatomical regions.
Methods: We analyzed three randomized trials on zinc acetate lozenges for the common cold administering zinc in
doses of 80–92 mg/day. All three trials reported the effect of zinc on seven respiratory symptoms, and three systemic
symptoms. We pooled the effects of zinc lozenges for each symptom and calculated point estimates and 95%
confidence intervals (95% CI).
Results: Zinc acetate lozenges shortened the duration of nasal discharge by 34% (95% CI: 17% to 51%), nasal
congestion by 37% (15% to 58%), sneezing by 22% (−1% to 45%), scratchy throat by 33% (8% to 59%), sore
throat by 18% (−10% to 46%), hoarseness by 43% (3% to 83%), and cough by 46% (28% to 64%). Zinc
lozenges shortened the duration of muscle ache by 54% (18% to 89%), but there was no difference in the
duration of headache and fever.
Conclusions: The effect of zinc acetate lozenges on cold symptoms may be associated with the local availability of
zinc from the lozenges, with the levels being highest in the pharyngeal region. However our findings indicate that the
effects of zinc ions are not limited to the pharyngeal region. There is no indication that the effect of zinc lozenges on
nasal symptoms is less than the effect on the symptoms of the pharyngeal region, which is more exposed to released
zinc ions.
Given that the adverse effects of zinc in the three trials were minor, zinc acetate lozenges releasing zinc ions at doses
of about 80 mg/day may be a useful treatment for the common cold, started within 24 hours, for a time period of less
than two weeks.
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Interest in zinc lozenges (as tablets that are intended to
be dissolved slowly in the mouth) for the treatment of
the common cold started from the serendipitous obser-
vation that the cold symptoms of a 3-year-old girl with
leukemia disappeared within a few hours when she slowly
dissolved a therapeutic zinc tablet in her mouth instead of
swallowing it [1]. The benefit appeared to be derived from
dissolving the tablet in the mouth, which implied that zinc
may have local effects in the pharyngeal region. This ob-
servation led the father of the child to conduct a random-
ized trial, which found that zinc lozenges significantly
shortened colds [1].
Subsequently a series of zinc lozenge trials were car-
ried out but with variable results. The composition of
the zinc lozenges differed between trials with some loz-
enges containing substances that tightly bind to zinc
ions, such as citric acid. Therefore, variation in the level
of free zinc ions has been proposed as one factor that
can explain the significant heterogeneity in the results of
the trials [2-10]. Acetate does not chemically bind to
zinc ions and therefore zinc acetate may be an ideal zinc
salt for composing lozenges that release high levels of free
zinc ions [6,9,10].
A recent meta-analysis investigated the role of zinc dos-
age on the effect of zinc lozenges on cold duration [11].
Five trials with zinc lozenges that contained low doses of
zinc, <75 mg/day, consistently found no effect from the
lozenges. In contrast, three trials with high doses of zinc,
>75 mg/day, as zinc acetate lozenges, consistently found
that colds were shortened by a mean of 42% [11]. Five
high-dose trials used zinc salts other than acetate and ob-
tained a mean 20% reduction in cold duration [11]. Two
other systematic reviews on zinc and the common cold
combined zinc lozenge trials with zinc syrup trials [12,13].
Those reviews however overlooked the fact that slowly
dissolving zinc lozenges may cause local effects in the
pharyngeal region, whereas rapidly swallowed syrup does
not. In addition, the two reviews had other severe limita-
tions [14-16].
Nasal administration of zinc shortened the duration of
colds in two studies [17,18], which implied that zinc can
have a local effect against colds within the nasal region.
Similarly, the effects of zinc lozenges may be local within
the pharyngeal region instead of being purely systemic.
Although the local effects of zinc in the nasal region are
of interest for the purposes of researching the mecha-
nisms of the effects of zinc, nasal zinc application might
cause anosmia [19,20] and nasal zinc application should
be discouraged unless application methods are devel-
oped that eliminate such a risk.
When zinc acetate lozenges dissolve in the mouth, zinc
ions are released into the saliva of the pharyngeal region
where the levels are consequently high. However, zinclozenges do not seem to increase the level of zinc in the
nasal mucosa ([6], p490). If the zinc ion concentration
of the mucosa determines the effect of zinc lozenges
on the specific symptoms on the particular anatomical
region, there might be substantial differences between the
effects of zinc on throat symptoms compared with nasal
symptoms.
The purpose of this meta-analysis is to investigate whether
zinc acetate lozenges have different effects on the duration
of common cold symptoms originating from different ana-
tomical regions.
Methods
Selection of the trials
This meta-analysis was restricted to placebo-controlled
trials on the effect of zinc acetate lozenges on natural
common cold infections in which the doses were >75 mg/
day of zinc ion. Previous searches of the literature [11-13]
identified three trials that fulfilled the inclusion criteria
[21-23] (Additional file 1). Table 1 summarises the charac-
teristics of the three included trials. No additional zinc
acetate trials were found by searching PubMed using the
free search terms “zinc” and “lozenge$” (Jan 2, 2015). This
was an analysis of published data and therefore no ethics
approval was needed. This study is reported according to
the PRISMA Statement [24].
Outcomes and extraction of data
Each of the three trials reported the total duration of
colds and the duration of the same respiratory and sys-
temic symptoms. The extracted original data are available
in Additional file 2. Petrus et al. [21] reported the results
to only one decimal place; more precise data were kindly
provided by Kenneth Lawson for the total duration of
colds on March 4, 2009 and for the duration of specific
symptoms of colds on April 11, 2014. Both authors of this
study checked the accuracy of the extracted data against
the original reports and by referring directly to Lawson’s
emails.
Statistical methods
Differences in the distributions of viruses and in the severity
of disease in different patient groups in addition to differ-
ences in outcome definitions cause considerable variation
in the recorded durations of colds in different untreated
patient groups. Therefore, the relative effect of zinc on the
common cold duration was calculated in percentages, be-
cause the relative effect adjusts for variations between the
patient groups and outcome definitions.
In the original study reports, the duration of each symp-
tom was reported in days. For this meta-analysis, the du-
rations were transformed to a percentage scale so that the
duration of each symptom in the corresponding placebo
group was 100%. Consequently the pooling of the three
Table 1 Characteristics of high dose zinc acetate lozenge trials
Trial Characteristics
Petrus et al.
(1998) [21]*
Methods Randomized, placebo-controlled, double-blind trial.
Participants Included in the analysis: 52 Zn and 49 placebo participants: 47 M 54 F, mean age 26 yr (range 18 to 54 yr). Participants were recruited
from the campus of the University of Texas through posted announcements. Exclusions: serious illnesses, organ transplants, disability.
Intervention Zn acetate: one lozenge contained 9 mg Zn. Placebo lozenges contained sucrose octaacetate. Participants were instructed to use 1
lozenge every 1½ hr while awake during day 0, then 1 lozenge every 2 hr while awake on following days. The mean number of lozenges
used per day by all participants was 9.9. Mean daily zinc dose was 89 mg/d. 97 of the 101 subjects started using zinc lozenges on the first
day of enrollment in the study (4 on day 2), but data on the length of time between onset of symptoms and enrollment is not available.
Common cold
definition
Presence of ≥2 of the following symptoms: nasal drainage, nasal congestion, cough, fever, myalgia, headache, sore throat, scratchy
throat, hoarseness, sneezing, malaise.
Prasad et al.
(2000) [22]
Methods Randomized, placebo-controlled, double-blind trial.
Participants Included in the analysis: 25 Zn and 23 placebo participants: 18 M 30 F, mean age 37 yr (SD 11 yr). Participants were students, staff, and
employees at Wayne State University, Michigan, who were ≥18 yr. Exclusions: pregnancy, a known immunodeficiency disorder, chronic
illnesses, previous use of zinc lozenges. Inclusion required that the cold had lasted for ≤24 hr.
Intervention Zn acetate: one lozenge contained 12.8 mg Zn. Placebo lozenges contained sucrose octaacetate. Participants were instructed to dissolve
1 lozenge in their mouth every 2 to 3 hr while awake. The mean number of lozenges used per day in the Zn group was 6.2. Mean daily
zinc dose was 80 mg/d.
Common cold
definition
Presence of ≥2 of the following symptoms: cough, headache, hoarseness, muscle ache, nasal discharge, nasal congestion, scratchy
throat, sore throat, sneezing, fever.
Prasad et al.
(2008) [23]
Methods Randomized, placebo-controlled, double-blind trial
Participants Included in the analysis: 25 Zn and 25 placebo participants: 16 M 34 F, mean age 35 yr (SD 14 yr). Participants were students, staff,
and employees at Wayne State University, Michigan, who were ≥18 yr. Exclusions: pregnancy, any known immune deficiency
disorder or chronic illness, previous use of zinc lozenges. Inclusion required that the cold had lasted for ≤24 hr.
Intervention Zn acetate: one lozenge contained 13.3 mg Zn. Placebo lozenges contained sucrose octaacetate. The packages were identical in
appearance except for the randomization numbers. Participants were asked to dissolve 1 lozenge in their mouth every 2 to 3 hr
while awake. The mean number of lozenges used per day in the Zn group was 6.9. Mean daily zinc dose was 92 mg/d.
Common cold
definition
Presence of ≥2 of the following symptoms: cough, headache, hoarseness, muscle ache, nasal discharge, nasal congestion, scratchy
throat, sore throat, sneezing, fever.
*Additional information about [21] was received from Kenneth Lawson on Jan 7, 2015.
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specific symptoms. The transformation to the percentage
scale is described in Additional file 2.
We pooled the effect of zinc acetate lozenges on the
specific symptoms by using the inverse-variance fixed-
effect option in the RevMan program [25] (Additional
file 3). Heterogeneity between the three studies was
assessed by using the χ2-test and the I2-statistic [26]. The
I2-statistic estimates the percentage of total variation
across studies that is due to true heterogeneity rather than
due to chance. A value of I2 greater than about 75% indi-
cates a high level of heterogeneity. Some of the RevMan
forest plots were redrawn with Gnuplot [27] for greater
clarity.
To compare the mean durations of the specific symp-
toms in the placebo groups of each trial, we transformed
the durations of the specific symptoms to a percentage
of the total mean common cold duration for each group
(Additional file 2). Thereafter the durations of the specificsymptoms for all three trials were pooled using the RevMan
program (Additional file 4). This pooling gave the dur-
ation of the specific untreated symptom as a percentage of
the total untreated common cold duration. Both authors
checked the accuracy of the calculations.
Results
Three studies were found which used zinc acetate lozenges
containing zinc in doses of over 75 mg/day. The trials were
randomized, placebo-controlled and double-blind, and
few drop-outs occurred in the trials (Tables 1 and 2). The
dose of zinc varied from 80 to 92 mg/day in the three
studies. In total, there were 102 participants in the zinc
groups and 97 participants in the placebo groups.
There was no substantial heterogeneity between the
three trials in the effect of zinc acetate lozenges on total
common cold duration (P = 0.2; I2 = 41%), and a pooled
estimate of a 42% reduction in the total duration of the
colds was obtained (Figure 1).
Table 2 Methodological characteristics of the included trials
Study, Domain of
interest
Description
Petrus et al. 1998 [21]*
Randomization Reported as a randomized trial, but the method of randomization was not described.
Allocation concealment Participants and personnel did not know to which group the participants were allocated.
Blinding of participants
and personnel
Reported as double-blind, which implies that participants and personnel were blinded.
Blinding of outcome
assessment
Blinded subjects recorded their symptoms every day.
Losses to follow-up 1 was lost to follow-up.
Prasad et al. 2000 [22]*
Randomization A Research-Assistant was responsible for randomization. This person did not see the patients and was not involved in collection
of clinical data. The subjects were randomized into zinc and placebo groups by the research assistant as they were recruited.
Allocation concealment Participants and personnel did not know to which group the participants were allocated.
Blinding of participants
and personnel
The Clinical Assistant who collected all of the clinical information and remained in touch with the subjects who were
recruited for the study remained completely blinded regarding the contents of the zinc and placebo pills.
Blinding of outcome
assessment
Blinded participants completed daily logs.
Losses to follow-up 2 in the placebo group dropped out on day 2.
Prasad et al. 2008 [23]*
Randomization A research consultant prepared the randomization code and the packages of medication. The packages were identical in
appearance except for the randomization numbers. This person did not see the patients and was not involved in collection
of clinical data. The subjects were randomized into zinc and placebo groups by the research assistant as they were recruited.
Allocation concealment Participants and personnel did not know to which group the participants were allocated.
Blinding of participants
and personnel
The Clinical Assistant who collected all of the clinical information and remained in touch with the subjects who were
recruited for the study remained completely blinded regarding the contents of the zinc and placebo pills.
Blinding of outcome
assessment
Blinded participants completed daily logs.
Losses to follow-up No drop outs.
*Additional information about the methods of [22,23] was received from Ananda Prasad on Dec 17, 2014 and of [21] from Kenneth Lawson on Jan 7, 2015.
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tomically so that the three symptoms of the nasal region are
at the top of the figure, followed by two throat symptoms,
and finally hoarseness (indicating laryngitis) and cough. In
the three nasal symptoms, there is no heterogeneity in the
zinc acetate lozenge effect between the trials (I2 < 3% forFigure 1 The effect of high dose zinc acetate lozenges on the duratio
vertical line indicates the placebo level. The horizontal lines indicate the 95
lines indicate the point estimate of the effect in the particular trial. The sizes o
shape indicates the pooled effect and the 95% CI. The pooled effect was
was transformed to the relative scale so that the duration in the respe
difference between zinc and placebo groups directly indicates the effect of
data and for the calculation of the relative mean and SD values for total comeach symptom). The pooled estimates indicate that zinc
acetate lozenges shorten nasal discharge by 34% and nasal
congestion by 37%, whereas the 22% shorter duration of
sneezing is not significantly different (Additional file 3).
The zinc lozenge effect on scratchy throat was not sub-
stantially heterogeneous between the three trials (I2 = 38%);n of the common cold. In the forest plot on the right side, the
% CI for the zinc effect and the squares in the middle of the horizontal
f the squares indicate the relative weights of the trials. The diamond
−42% (95% CI: −35% to −48%; P = 10−33). The duration of colds
ctive placebo group was given the value of 100%. Thus the
zinc lozenges in percentages. See Additional file 2 for the extraction of
mon cold duration.
Figure 2 The effect of high dose zinc acetate lozenges on the duration of respiratory symptoms of the common cold. In the forest plots
on the right side, the vertical line indicates the placebo level. The horizontal lines indicate the 95% CI for the zinc effect and the square in the
middle of the horizontal line indicates the point estimate of the effect in the particular trial. Arrows at the end of the horizontal lines indicate that the
95% CI extends out of the forest plot. The sizes of the squares indicate the relative weights of the trials. The diamond shape indicates the pooled effect
on the symptoms and its 95% CI. The duration of symptoms was transformed to the relative scale, thus the duration in the respective placebo group
was given the value of 100%. The difference between zinc and placebo groups thus directly indicates the effect of zinc lozenges in percentages. See
Additional file 2 for the extraction of data and for the calculation of the relative mean and SD values for the duration of symptoms, and Additional
file 3 for the raw data and the estimates for individual studies.
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calculated (Figure 2). The effect of zinc on sore throat was
significantly heterogeneous with I2 = 72% (P = 0.03), and
the pooled estimate of an 18% shorter duration of sore
throat was not significantly different.
The effect of zinc lozenges on hoarseness is not substan-
tially heterogeneous (I2 = 41%). None of the three trialsindividually found a significant effect on hoarseness, but
the pooled estimate indicates a 43% decrease in the dur-
ation of hoarseness.
Cough was not influenced by zinc in the Petrus et al.
study, whereas in the two studies by Prasad et al. a sig-
nificant reduction in the duration of cough was observed
(Figure 2). However, the confidence intervals were wide
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I2 = 64% (P = 0.06). The pooled result indicates a 46% re-
duction in the duration of cough.
Figure 3 shows the effect of zinc acetate lozenges on
systemic symptoms. There was no heterogeneity between
the three studies on the effects of zinc lozenges on fever,
muscle ache or headache (I2 = 0% for each symptom). The
pooled effects indicate that zinc shortens the duration of
muscle ache by 54%, whereas the 13% shorter duration of
headaches and the 35% shorter duration of fevers were
not significantly different between the zinc acetate and
placebo groups.
Figure 4 summarizes the effects of zinc acetate loz-
enges on the respiratory and systemic symptoms. There
is no heterogeneity in the effect of zinc on the seven re-
spiratory symptoms with I2 = 0% (Additional file 3, p. 4),
indicating that the variation in the zinc effect on the
seven respiratory symptoms might be just due to ran-
dom variation. The pooled effects on sneezing and sore
throat were not significant; however, the 95% CIs for
both symptoms are wide and they are not inconsistentFigure 3 The effect of high dose zinc acetate lozenges on the duratio
on the right side, the vertical line indicates the placebo level. The horizonta
middle of the horizontal line indicates the point estimate of the effect in th
that the 95% CI extends out of the forest plot. The sizes of the square
indicates the pooled effect on the symptoms and its 95% CI. The dura
duration in the respective placebo group was given the value of 100%
indicates the effect of zinc lozenges in percentages. See Additional file
mean and SD values for the duration of symptoms, and Additional filewith the effects on other symptoms. There was strong
evidence that zinc acetate lozenges shortened the dur-
ation of muscle ache. The 95% CIs for headache and
fever are wide.
There is substantial variation between the mean dura-
tions of individual symptoms. For example, in the pla-
cebo group of the Prasad et al. (2008) trial, muscle ache
lasted for a mean of 2.0 days, but cough lasted for
5.1 days; whereas the total duration of colds was 7.1 days
(Table 3). Therefore the percentage effect of zinc on the
specific symptoms should be considered together with
the duration of untreated symptoms. Figure 5 shows the
duration of symptoms so that they are normalized by
the total duration of the colds in the three trials. For ex-
ample, in the three trials, mean nasal discharge lasted
for 73% (95% CI 60% to 85%) of the total common cold
duration.
The symptom durations were longest for nasal dis-
charge, nasal congestion and cough so that each of them
lasted for more than half of the total duration of the
common cold (Figure 5). Thus, time-wise, the effect ofn of systemic symptoms of the common cold. In the forest plots
l lines indicate the 95% CI for the zinc effect and the square in the
e particular trial. Arrows at the end of the horizontal lines indicate
s indicate the relative weights of the trials. The diamond shape
tion of symptoms was transformed to the relative scale, thus the
. The difference between zinc and placebo groups thus directly
2 for the extraction of data and for the calculation of the relative
3 for the raw data and the estimates for individual studies.
Figure 4 The effect of high dose zinc acetate lozenges on the duration of common cold symptoms. The pooled estimates and their 95%
CIs are shown in this figure. The horizontal lines indicate the 95% CI for the effect and the squares in the middle of the horizontal lines indicate
the point estimates of the effect on the particular respiratory and systemic symptoms. See Additional files 2 and 3 for the calculations.
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portant than the effect on shorter-lived symptoms. These
three longest-lasting respiratory symptoms were all short-
ened by 34% or more, with particularly small P-values
(Figures 2 and 4). The systemic symptoms lasted for
only a quarter or less of the total common cold duration
(Figure 5). Therefore, the 54% reduction on muscle ache
corresponded to a shorter time period free of the symp-
tom than the 34% to 46% effects on the longer-lasting re-
spiratory symptoms.
Calculating the relative effect of zinc lozenges is the
best approach to pool the results of the three trials since
it adjusts for baseline variations in symptom duration.
On the other hand, the absolute effect of zinc on the
days saved of illness is also important as it has practical
relevance for patients. As an illustration of the effect of
zinc on both the days saved and the percentage shorten-
ing of symptoms, Table 3 shows the findings of the most
recent study by Prasad et al. (2008). Only those out-
comes on which zinc had a significant influence are
shown, since the point estimates of the effect are useful
only for them. Muscle ache was shortened by 1.2 days,Table 3 The effect of zinc acetate lozenges on common cold s
Treatment group
Zinc Placebo
(Days; mean) (Days; mean)
Total duration 4.00 7.12
Nasal discharge 3.00 4.56
Cough 2.16 5.08
Muscle ache 0.80 2.00which is less than half of the 2.9 day effect on cough, yet
the relative effect is the same for both. This is explained
by the substantially longer mean duration of cough, so
that the same relative effect corresponds to more actual
days saved from coughing. Nasal discharge was short-
ened by 1.5 days, which is half of the effect on cough. In
this comparison the non-treated duration is essentially
the same, but the relative effect is smaller for nasal
discharge.
Discussion
Given that zinc lozenges are slowly dissolved in the
pharyngeal region, and that the effects of zinc seem to be
local, there might be variation in the effects of zinc loz-
enges on common cold symptoms in different anatomical
regions. Contrary to such reasoning, the effects of zinc
lozenges on the nasal symptoms were not significantly dif-
ferent compared with the symptoms that originated in the
lower anatomical regions. Furthermore, there was no het-
erogeneity between the effect of zinc on the seven respira-
tory symptoms with I2 = 0%. This indicates that the lack of
significance in the effects on sneezing and sore throatymptoms in the Prasad et al. (2008) study [23]
Effect of zinc Effect of zinc
(Days; mean, 95% CI) (%; mean, 95% CI)
−3.12 (−2.48, −3.76) −43% (−34%, −53%)
−1.56 (−0.22, −2.90) −34% (−4%, −64%)
−2.92 (−1.58, −4.26) −57% (−30%, −84%)
−1.20 (−0.20, −2.20) −60% (−9%, −110%)
Figure 5 The duration of the specific symptom as a proportion of the total common cold duration (set as 100%) of the placebo
groups. The left side of the figure shows the duration of the symptom as a proportion of the total common cold duration, and the right side
shows the same information as a forest plot. On the scale of this figure, 100% corresponds to the total duration of the common cold of the
placebo groups. The duration of symptoms was calculated as follows. First, the duration of the specific symptom was calculated as the
percentage of the total common cold duration for the placebo group (5.1 days in Petrus et al. [21], 8.1 days in Prasad et al. (2000) [22],
and 7.1 days in Prasad et al. (2008) [23]). Then the relative duration of each specific symptom was pooled using the RevMan program. There was no
heterogeneity between the three trials in the relative duration of untreated nasal discharge, sneezing, sore throat, hoarseness, muscle pain, headache,
and fever with P > 0.05 for the test of heterogeneity. The relative durations of untreated nasal congestion (I2 = 85%), scratchy throat (I2 = 74%), and
cough (I2 = 68%) were significantly different in the three trials. See Additional files 2 and 4 for the calculations.
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dence intervals substantially overlap with all the other
symptoms (Figure 4). Nevertheless, the substantial overlap
between the 95% CIs and the I2 = 0% do not necessarily
indicate that the size of the effect of zinc lozenges on all
the seven respiratory symptoms is the same. Instead, the
sizes of the studies were probably insufficient to reveal
modest differences in the effects on the seven respiratory
symptoms.
The anatomical origin of the three nasal symptoms, sore
and scratchy throat, and hoarseness (laryngitis) is evident.
However, cough has a more ambiguous anatomical origin.
It can originate from different anatomical regions with dif-
ferent pathologies, and thus is not similarly informative of
the possible locations of zinc lozenge effects [28,29].
The common cold is usually caused by respiratory vi-
ruses that have over 100 serotypes [30]. The distribution
of viruses varies over time and geography and therefore
the common cold episodes in different controlled trials
have different aetiologies. In addition, variations in out-
come definitions also generate variation between trials
and the interventions are also not identical. For these rea-
sons, variation between trials investigating the effects of
common cold treatments is to be expected. Nevertheless,only for sore throat and cough was there substantial het-
erogeneity in the effect of zinc acetate lozenges over the
three included studies with I2 above 60% (Figure 2).
The most common cause for the common cold is
rhinovirus, and usually the most bothersome symptom
of rhinovirus infections is nasal discharge [31]. Therefore,
the 34% reduction in the duration of nasal discharge, with
no heterogeneity between the three trials, is a particularly
important effect (Figure 4). The common cold is the most
common cause of acute cough [29] and therefore the esti-
mated 46% reduction in the duration of cough is also very
important (Figure 4).
In the three trials analyzed, the systemic symptoms of
colds were much shorter than the respiratory symptoms.
Muscle ache and headache lasted for a quarter and fever
lasted for less than a tenth of the total common cold dur-
ation (Figure 5). Only muscle ache was shortened signifi-
cantly by zinc. Nevertheless, it seems probable that the
three studies did not have sufficient statistical power to
estimate the effect of zinc acetate lozenges on headache
and fever since the pooled 95% CIs were wide for both
symptoms.
All included studies were randomized double-blind,
placebo-controlled trials, and the level of drop outs was
Hemilä and Chalker BMC Family Practice  (2015) 16:24 Page 9 of 11none or few. Therefore, the risk of bias in the three in-
cluded trials is low (Table 2). All of the three trials re-
ported seven of the most important respiratory symptoms
(Figure 2). Zinc did not have a significant effect on 13 of
21 respiratory symptoms across the 3 studies, yet the data
on the 13 symptoms were still reported. Thus, all 7 symp-
toms were reported for each of the 3 studies. Conse-
quently, there is no basis to assume that reporting bias
might confound our analysis of these specific common
cold symptoms.
Two of the included trials [22,23] only enrolled partici-
pants who had had cold symptoms for less than 24 hours.
The third study did not describe the duration of illness
before zinc administration, but most of the participants
started treatment on the first day of enrolment in the
study [21]. Hence it is possible that the observed benefit
of zinc in the two studies [22,23] might not have oc-
curred had the delay between the onset of the common
cold and the initiation of zinc treatment been longer
than one day.
In the USA, the recommended dietary zinc intake is
11 mg/day for men and 8 mg/day for women [32]. Thus,
the 80 to 92 mg/day doses used in the zinc acetate loz-
enge trials are substantially higher than the recom-
mended daily intakes. However, in several clinical trials
zinc has been administered to patients at a dose of
150 mg/day for months [33-37]. A decrease in copper
levels and haematological changes have been reported as
adverse effects of long-term high dose zinc administra-
tion, but those changes were completely reversed with
the cessation of zinc intake [38-42]. Thus, given that
150 mg/day of zinc administration for months does not
cause permanent harm, it seems plausible that the use of
about 80 mg/day of zinc for up to two weeks in the form
of zinc acetate lozenges is unlikely to cause serious ad-
verse effects.
In some zinc lozenge trials the lozenges caused short-
term adverse effects, such as bad taste, but the bad taste
can be explained by the specific lozenge composition
and does not necessarily reflect the effects of zinc ions
themselves [9,10]. None of the high dose zinc acetate
lozenge trials reported bad taste to be a problem and
there was no substantial difference between the zinc and
placebo groups in the recorded adverse effects, and only
a few drop-outs occurred. Furthermore, if a common
cold patient suffers from acute adverse effects such as
bad taste, the patient can simply stop taking the zinc
acetate lozenges.
Evidence-based medicine focuses primarily on the effect
of interventions on clinically relevant outcomes in con-
trolled trials, which is also the approach of this meta-
analysis. Nevertheless, the potential biological mechanisms
are also of interest. Although the mechanism of zinc in the
alleviation of colds is not known, possible mechanismshave been proposed. In laboratory studies zinc inhibited
the replication of respiratory viruses and enhanced the ef-
fect of interferons [10,43,44]. Non-immune mechanisms
have also been proposed to explain the effect of zinc loz-
enges on the common cold [10,45,46]. However, the lack
of well-formulated mechanistic explanations should not
hamper the implications of these three randomized trials
with clinically relevant outcomes.
Although these three trials that used high dose zinc
acetate lozenges show that an appropriate lozenge com-
position can substantially shorten the duration of vari-
ous common cold symptoms, many zinc lozenges on the
US market either have too low a dose of zinc or contain
ingredients that tightly bind to zinc ions, such as citric
acid [10]. Therefore, the full benefit seen in the three
high dose zinc acetate trials may not be easy to actualize
until high dose zinc acetate lozenges are more widely
available on the market.
Conclusions
We found no evidence that the effect of high dose zinc
acetate lozenges varies between the respiratory symp-
toms originating from different anatomic regions. Given
that there were only few and minor adverse effects in
the three randomized trials, zinc acetate lozenges may
be a useful treatment option for the common cold. Since
two of the included studies started zinc treatment within
24 hours of the onset of the common cold, the strongest
evidence of benefit is for such rapid initiation of zinc ad-
ministration. More research is needed to find optimal
lozenge compositions and treatment strategies.
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